IF allogeneic iPSC-derived NK cells co-engineered to constitutively express (1) the chemokine receptor CCR2 for active homing and (2) a second-generation uPAR-targeting CAR (anti-uPAR scFv fused to 4-1BB/CD3ζ signaling domains; designated CCR2×uPAR-CAR-iNK), delivered intravenously at 5×10⁶ cells per dose across three infusions (Day 0, Day 7, Day 14), is administered to 18–20-month-old male C57BL/6J mice with confirmed senescent burden (SA-β-gal positivity and elevated circulating CCL2),
THEN a ≥50% reduction in uPAR-positive senescent cell density within visceral adipose tissue, liver, and lung (quantified by immunofluorescence and flow cytometry for p21/p16/uPAR co-positivity), accompanied by ≥40% reduction in tissue CCL2, IL-6, and MMP-3 protein levels (SASP panel by Luminex), and measurable functional improvements in glucose tolerance (GTT AUC) and respiratory elastance (FlexiVent), will be observed within 6 weeks of first infusion,
BECAUSE the following causal chain operates:
-
Aged SASP-high senescent cells constitutively secrete CCL2 (MCP-1) into tissue interstitia, creating sustained chemokine gradients particularly dense in visceral adipose, steatotic liver, and fibrotic lung — gradients that exceed plasma CCL2 concentrations by 5–10-fold in local tissue. This establishes a targetable beacon for receptor-mediated trafficking. (Senescent cells drive chronic inflammation via SASP)[https://doi.org/10.1172/jci64098]
-
uPAR (PLAUR) is broadly and selectively upregulated on senescent cells across multiple tissues and senescence induction modes (oncogene-ind





























